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Cisplatin is a well- known anticancer drug used to treat various cancers. However, 
development of cisplatin resistance has hindered the efficiency of this drug in cancer 
treatment. Development of chemoresistance is known to involve many signaling 
pathways. Recent attention has focused on microRNAs (miRNAs) as potentially im-
portant upstream regulators in the development of chemoresistance. CD44 is one of 
the gastric cancer stem cell markers and plays a role in regulating self- renewal, tumor 
initiation, metastasis and chemoresistance. The purpose of the present study was to 
examine the mechanism of miRNA- mediated chemoresistance to cisplatin in CD44- 
positive gastric cancer stem cells. We sorted gastric cancer cells according to level of 
CD44 expression by FACS and analyzed their miRNA expression profiles by microar-
ray analysis. We found that miR- 193a- 3p was significantly upregulated in CD44(+) 
cells compared with CD44(−) cells. Moreover, SRSF2 of miR- 193a- 3p target gene was 
downregulated in CD44(+) cells. We studied the modulation of Bcl- X and caspase 9 
mRNA splicing by SRSF2 and found that more pro- apoptotic variants of these genes 
were generated. We also found that downstream anti- apoptotic genes such as Bcl- 2 
were upregulated, whereas pro- apoptotic genes such as Bax and cytochrome C were 
downregulated in CD44(+) cells compared to CD44(−) cells. In addition, we found 
that an elevated level of miR- 193a- 3p triggered the development of cisplatin resist-
ance in CD44(+) cells. Inhibition of miR- 193a- 3p in CD44(+) cells increased SRSF2 
expression and also altered the levels of multiple apoptotic genes. Furthermore, inhi-
bition of miR- 193a- 3p reduced cell viability and increased the number of apoptotic 
cells. Therefore, miR- 193a- 3p may be implicated in the development of cisplatin re-
sistance through regulation of the mitochondrial apoptosis pathway. miR- 193a- 3p 
could be a promising target for cancer therapy in cisplatin- resistant gastric cancer.
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1  | INTRODUC TION
To date, chemotherapy has been the primary strategy for can-
cer treatment. However, chemoresistance is a major obstacle 
to chemotherapy and is one of the main causes of its failure. 
Chemoresistance has been shown to develop by three different 
mechanisms. These mechanisms include deterioration of water- 
soluble drugs resulting in reduced drug uptake, changes in cells 
that affect the cytotoxicity of drugs, such as decreased apoptosis 
or increased DNA repair action, and increased efflux of hydropho-
bic drugs by ATP- binding cassette transporters.1 However, the 
modulation of chemoresistance is still a topic of investigation and 
complete understanding of the mechanisms underlying the devel-
opment of chemoresistance has the potential to be enormously 
helpful to cancer therapy.
Cisplatin (also known as CDDP), a platinum compound, is one 
of the most commonly used anticancer drugs. Cisplatin was dis-
covered in the 1840s and has been used to treat various types 
of cancers. Cisplatin binds and crosslinks DNA, thereby inducing 
apoptosis.2 In advanced gastric cancer, combination chemother-
apies including cisplatin have been shown to result in improved 
survival times and response rates.3,4 Cisplatin resistance has been 
thoroughly investigated and many different mechanisms of cis-
platin resistance have been proposed (pre- , on- , post- , and off- 
target).5 Apoptosis refers to programmed cell death and is distinct 
from other types of cell death such as necrosis. Apoptosis can 
occur through two different pathways, termed the intrinsic and 
extrinsic pathways. The intrinsic apoptosis pathway is related to 
mitochondrial permeability and is controlled by Bcl- 2 family pro-
teins, which regulate permeabilization of the mitochondrial outer 
membrane.6 Reactive oxygen species (ROS) can also create pores 
in the mitochondrial membrane, triggering apoptosis.7 In the ex-
trinsic apoptosis pathway, death receptors convey death signals 
from the cell surface to intracellular mediators of this pathway.8 
Cells undergoing apoptosis show distinct morphological changes. 
In particular, apoptotic cells show small DNA fragments composed 
of compacted nuclear contents. Apoptotic cells also migrate and 
form apoptotic bodies.9
MicroRNAs (miRNAs) are 22- nucleotide non- coding RNAs that 
regulate cellular processes by targeting sequence- specific mRNAs. 
Generally, miRNAs inhibit translation by binding to the 3′- 3′UTR of 
their target mRNAs.10 Several miRNAs have been reported to cause 
drug resistance or suppress apoptosis.11 miRNAs regulate chemore-
sistance by targeting tumor suppressor or drug transporter genes.12 
High expression of microRNA (miR)- 221/222 has been shown to 
confer tamoxifen resistance to breast cancer cells through a mecha-
nism that targets p27.13,14 Multidrug resistance in gastric cancer cells 
has also been shown to be associated with decreased expression of 
miR- 15b and miR- 16.15
CD44 is one of the gastric cancer stem cell markers and is critical 
in regulating self- renewal, tumor initiation, metastasis and chemo-
resistance. In addition, CD44 correlates with poor prognosis in var-
ious human cancers, including breast, brain, colon, pancreatic, and 
gastric cancers.16 In our previous study, we reported upregulated 
CD44 expression in gastric cancer cells and the miR- 106b family was 
significantly upregulated in CD44- positive cancer cells.17 Although 
miRNA regulation has been examined as a cancer stem cell charac-
teristic, the mechanism of the miR- 193a- 3p- dependent cisplatin re-
sistance response underlying gastric cancer stemness has not been 
fully studied.
Herein, we evaluated cisplatin resistance in CD44(+) gastric 
cancer cells and found that upregulation of miR- 193a- 3p was as-
sociated with cisplatin resistance. We analyzed the expression 
levels of miR- 193a- 3p target such as SRSF2 and various isoforms 
of downstream SRSF2 targets, including pro- and anti- apoptotic 
genes. Furthermore, we examined the mechanisms of apoptosis reg-
ulation by miR- 193a- 3p, we inhibited miR- 193a- 3p in CD44(+) cells 
and measured cell viability after cisplatin treatment. We found that 
miR- 193a- 3p might have potential as a therapeutic target to treat 
diseases such as cisplatin- resistant gastric cancer through regulation 
of the mitochondrial apoptosis pathway.
2  | MATERIAL S AND METHODS
2.1 | Cell culture
MKN45 (KCLB 80103), AGS (ATCC CRL- 1739) and KATO III (KCLB 
30103) gastric cancer cells were maintained in RPMI- 1640 medium 
(Thermo Scientific, Rockford, IL, USA) supplemented with 10% FBS 
(Thermo Scientific) and 1% penicillin- streptomycin sulfate (Thermo 
Scientific). All cultures were maintained in a 37°C incubator supple-
mented with 5% CO2.
2.2 | Flow cytometry analysis and FACS
For flow cytometry, approximately 80% confluent cells in a 100- mm 
cell plate were washed with PBS. Cells were then detached from 
plates using trypsin- EDTA and centrifuged at 4°C. Cell pellets were 
resuspended in HBSS (Gibco, Grand Island, NY, USA) supplemented 
with 1 mM HEPES (Gibco) and 2% FBS and filtered with a 40- μm 
mesh filter (BD Biosciences, San Jose, CA, USA). Cells were stained 
with a 400- fold dilution of anti- CD44- FITC (BD Biosciences) and in-
cubated for 30 minutes in a 37°C incubator supplemented with 5% 
CO2. The cells were then washed with HBSS and resuspended in 
HBSS supplemented with 1 mM HEPES, 2% FBS and 1% penicillin- 
streptomycin sulfate. The cells were analyzed and sorted immedi-
ately with the FACS Aria III (BD Biosciences).
2.3 | MicroRNA microarray
Total RNA from CD44(+) and CD44(−) MKN45 cells was prepared 
using TRIzol reagent according to the manufacturer’s instructions. 
Microarrays were carried out using the Agilent Human miRNA 
8 X 60K (Rel 16.0 V2) platform (Agilent Technologies, Palo Alto, 
CA, USA). RNA hybridizations were done with the Human mi-
croRNA Microarray Kit (Agilent Technologies) according to the 
664  |     LEE Et aL.
manufacturer’s protocol. Arrays were scanned on an Agilent C scan-
ner. Images were quantified and data were processed using Agilent 
Feature Extraction Software (v 10.10.1.1). Raw data were extracted 
using software provided by the Agilent Feature Extraction Software 
(v 10.7.1.1). Selected miRNAgTotalGeneSignal values were logarith-
mically transformed and normalized by the quantile method. Each 
comparative analysis between test sample and control sample was 
carried out using fold- change. Hierarchical cluster analysis was car-
ried out using complete linkage and Euclidean distance as a measure 
of similarity.
2.4 | Tissue microarray construction from gastric 
cancer patients
In order to evaluate the relationship between the clinicopathological 
characteristics of gastric cancers and the expression of CD44 in vivo, 
we carried out immunohistochemical (IHC) staining for CD44 using 
tissue microarray (TMA). TMA were constructed from 277 pairs of 
gastric cancer tissue samples and corresponding normal tissues that 
were obtained from patients who had undergone curative surgery 
for gastric cancer at Yonsei University, Severance Hospital between 
April 2001 and December 2003. This study was approved by the 
Institutional Review Board of Severance Hospital. TMA were con-
structed as previously described. On H&E- stained slides of tumors, 
a representative area was selected and the corresponding spot was 
marked on the surface of the paraffin block. Using a biopsy nee-
dle, the selected area was punched out and a 2- mm tissue core was 
placed into an 8 × 6 recipient block. Gastric cancer tissues and cor-
responding normal tissues were then extracted. Each tissue core 
was assigned a unique TMA location number that was linked to a 
database containing other clinicopathological data.
2.5 | Immunohistochemistry assay
Tissue microarrays blocks were sectioned at a thickness of 3 μm 
and automated immunostaining done with Ventana Benchmark XT 
(Ventana Medical Systems, Tucson, AZ, USA) with antibody against 
CD44 (1:100; Cell Marque, Rocklin, CA, USA). All slides were de-
tected with ultraView universal DAB kit (Ventana Medical Systems) 
and counterstained with hematoxylin. IHC results were scored on 
tumor cells with cytoplasmic staining as follows: 0, faint staining in-
tensity in less than 5% of cells; 1+, weak staining in 5%- 10% of cells; 
2+, moderate staining in 10%- 50% of cells; 3+, strong staining in 
more than 50% of cells. Tumor was considered as positive when the 
score was 2+ or 3+, negative when the score was 0 or 1+.
2.6 | Real- time PCR
Total RNA was extracted from cells using TRIzol reagent (Invitrogen, 
Carlsbad, CA, USA) according to the manufacturer’s instructions. 
First- strand cDNA was synthesized using oligo(dT) primers and 
Superscript II reverse transcriptase (Invitrogen). Real- time PCR 
was carried out with a PCR mixture containing each primer (1 μM) 
and SYBR Green Master Mix (Applied Biosystems, Foster City, CA, 
USA). Thermocycling conditions included incubations at 95°C for 
10 seconds and 60°C for 60 seconds that were carried out using 
a StepOnePlus real- time PCR machine (Applied Biosystems). Each 
sample was examined in triplicate and the amount of PCR product 
was normalized with respect to β- actin as an internal control. Real 
time PCR primers are shown in Table 1.
cDNA for the miRNA assay was synthesized using the TaqMan 
MicroRNA Reverse Transcription Kit (Applied Biosystems) with miR- 
193a- 3p and U6- specific primers (Applied Biosystems), according to 
the manufacturer’s instructions. Real- time PCR for miRNA quanti-
fication was carried out with the TaqMan Universal Master Mix II 
(Applied Biosystems). The amplifications were conducted at 95°C 
for 10 seconds and at 60°C for 60 seconds using an AB7500 real- 
time PCR system (Applied Biosystems). Each sample was examined 
in triplicate and the amount of PCR product was normalized with 
respect to U6 as an internal control.
2.7 | Western blot analysis
After washing with PBS, cells were harvested and resuspended in lysis 
buffer (50 mM Tris- Cl [pH 7.5], 150 mM NaCl, 1 mM EDTA [pH 8.0], 
1% Triton X- 100, 1 mM PMSF, 1 mM Na3VO4 and protease inhibitor 
cocktail [Roche Molecular Biochemicals, Indianapolis, IN, USA]). After 
quantifying the amount of protein in each lysate, equal amounts of 
TABLE  1 Primer sequences
Gene Direction Sequence (5′- 3′)
SRSF2 F AACCTGACCTACCGCACCTC
R TGTCGTGAAAGCGAACGAAG
E2F1 F TGACGTGTCAGGACCTTCGT
R GCTGATCCCACCTACGGTCT
E2F6 F TCAGGCCTTCCATGAACAGA
R AGGTCCCGACACCTTCAGAC
MCL1 F CAGAGGAGGAGGAGGACGAG
R CATTGGCTTTGTGTCCTTGG
PCNA F GGACTCGTCCCACGTCTCTT
R GCGTTATCTTCGGCCCTTAG
Bcl- XL F ATCAATGGCAACCCATCCTG
R TTGTCTACGCTTTCCACGCA
Caspase 9a F AGTGGACATTGGTTCTGGAG
R CTTCTCACAGTCGATGTTGG
Bax F TGATCAGAACCATCATGGGC
R CAAAGATGGTCACGGTCTGC
Cytochrome C F GGAGGCAAGCATAAGACTG
R GTCTGCCCTTTCTCCCTTCT
Bcl- 2 F CCGTTGGCCCCCGTTGCTTT
R CTGGCGGAGGGTCAGGTGGA
β- Actin F TTGCCGACAGGATGCAGAAG
R AGGTGGACAGCGAGGCCAGG
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protein were prepared by heating the samples at 95°C after the ad-
dition of SDS sample buffer (62.5 mM Tris- Cl [pH 6.8], 2% SDS, 10% 
glycerol, β- mercaptoethanol and 0.002% bromophenol blue). Samples 
were loaded onto 8% SDS- PAGE gels for SRSF2 and 12% SDS- PAGE 
gels for Bcl- XL, Bax, Bcl- 2, cytochrome C, cleaved caspase- 3 and 
cleaved caspase- 9. Samples were then transferred to PVDF mem-
branes. Antibodies used included SRSF2 (1:1000; BD Biosciences), Bcl- 
XL (1:1000; Cell Signaling, Danvers, MA, USA), Bax (1:1000; Abcam, 
Cambridge, UK), Bcl- 2 (1:1000; Santa Cruz Biotechnology, Santa Cruz, 
CA, USA), cytochrome C (1:1000; Cell Signaling), cleaved caspase- 3 
(1:1000; Cell Signaling), cleaved caspase- 9 (1:1000; Cell Signaling) and 
β- actin (1:2000; Santa Cruz Biotechnology) as a loading control.
2.8 | Immunofluorescence assay
Cells were seeded on glass coverslips in six- well plates. After an 
overnight incubation, cells were washed with PBS three times, fixed 
in 4% formaldehyde for 10 minutes and permeabilized in 0.1% Triton 
X- 100 in PBS for 3 minutes. Cells were washed three times with 
PBS, blocked with 1% BSA in PBS and then incubated with primary 
antibodies overnight at 4°C. After washing with PBS, cells were in-
cubated with FITC- conjugated secondary antibodies for 1 hour at 
room temperature. Mitochondria were stained with Mitotracker 
(Invitrogen) at a 50 nM working concentration for 10 minutes. Slides 
were mounted with DAPI. All samples were photographed using 
a Zeiss LSM 700 confocal microscope (Carl Zeiss, Oberkochen, 
Germany).
2.9 | MicroRNA inhibitor transfection
MicroRNA inhibitor was purchased from GenePharma (Applied 
Biosystems, Shanghai, China). Cells were seeded into six- well plates 
and incubated overnight. The cells were transfected with miR- 
193a- 3p inhibitor (ACUGGGACUUUGUAGGCCAGUU) and nega-
tive control (CAGUACUUUUGUGUAGUACAA; Applied Biosystems) 
using Lipofectamine 2000 (Invitrogen) according to the manufactur-
er’s instructions. After 48 hours, the cells were harvested for RNA 
and protein isolation.
2.10 | Annexin V apoptosis detection assay
Cells were transfected with a miR- 193a- 3p inhibitor or a negative 
control and incubated for 24 hours. Cells were then treated with 
or without cisplatin (3 μg/mL) and subsequently stained using the 
Annexin V- FITC Apoptosis Detection Kit I (BD Biosciences) accord-
ing to the manufacturer’s instructions. Samples were analyzed by 
flow cytometry using the LSR II Flow Cytometer (BD Biosciences). 
Each experiment was independently carried out three times.
2.11 | MTS assay
Cells were seeded into 96- well plates, incubated overnight and then 
treated with cisplatin (2 or 2.5 μg/mL). After 72 hours, cells were 
incubated with CellTiter 96 AQueous One cell proliferation (MTS) assay 
solution (Promega, Madison, WI, USA) for 1- 2 hours in a 37°C incubator, 
supplemented with 5% CO2. Absorbance values were then measured at 
490 nm. Each experiment was independently carried out three times.
2.12 | Luciferase assay
The miR- 193a- 3p seed sequences (5- AATTTGGGTCTTTGCGGG
CGAGATGAT- 3 and 5- CTAGATCATCTCGCCCGCAAAGACCCA- 
3) were annealed and inserted into the EcoRI and XbaI sites of the 
CMV promoter- driven firefly luciferase reporter, pcDNA3.1- luc, to 
make the miR- 193a- 3p- luciferase reporter constructs. The SRSF2 
sequences (5- GGGTGGTACCGTCAGCTCTCCTCGGGGCGAAG- 3 
and 5- GTACAAGCTTTCTCAGG CAGTTGCCTTCCGCG- 3) were an-
nealed and inserted into the XhoI or HindIII sites of the pGL3 basic 
vector to make the SRSF2- luciferase reporter constructs.
Cells were seeded into six- well plates and incubated overnight. 
The cells were cotransfected with 2 μg firefly luciferase reporter 
constructs, 0.2 μg Renilla luciferase constructs or miR- 193a- 3p in-
hibitor, negative control (Applied Biosystems) using Lipofectamine 
2000 (Invitrogen) according to the manufacturer’s instructions. 
The Renilla luciferase constructs were used as a transfection effi-
ciency control. After 24 hours, luciferase activity of cell lysates was 
measured using the Dual Luciferase Reporter System (Promega). 
Luminescence was measured with a Centro luminometer (Berthold, 
Bad Wildbad, Germany). Results are expressed as the averages of the 
ratios of the activities from triplicate experiments. Firefly luciferase 
activities were standardized with the Renilla luciferase activities.
2.13 | Nuclear morphology
Cells were seeded on glass coverslips in six- well plates. The miR- 
193a- 3p inhibitor or negative control was transfected into the 
cells. After 24 hours, cells were treated with 3 μg/mL cisplatin 
for 48 hours. Cells were fixed in 4% formaldehyde for 10 minutes 
and permeabilized in 0.1% Triton X- 100 in PBS for 3 minutes. The 
slides were mounted with DAPI and observed under a fluorescence 
microscope.
2.14 | Statistical analysis
All experiments were done more than three times. All bars are ex-
pressed as means ± standard deviations. Two- tailed Student’s t test 
was used for statistical analysis. A statistical difference, represented 
as an asterisk (*) was considered significant when P < .05.
3  | RESULTS
3.1 | MicroRNA- 193a- 3p is upregulated in CD44(+) 
gastric cancer cells
To investigate the level of CD44 in gastric cancer cells, we sorted 
MKN45, AGS and KATO III cells into CD44(+) and CD44(−) cells. In 
666  |     LEE Et aL.
MKN45 cells, level of the CD44(+) population was higher than in 
KATO III and AGS cells (Figure 1A). To confirm the presence of CD44- 
positive cancer cells in clinically retrieved gastric cancer tissues, we 
carried out IHC to evaluate the level of CD44- expressing cancer 
cells using TMA. The TMA used in this research consisted of 277 
pairs of gastric cancer tissue samples and corresponding normal tis-
sues that were obtained from patients who had undergone curative 
surgery for gastric cancer at Yonsei University, Severance Hospital 
between April 2001 and December 2003. Immunohistochemistry of 
TMA tissue showed that gastric cancer tissues showed varying de-
grees of CD44 immunoexpression in gastric cancer cells in vivo: 5% 
or less in 141 cases (51%), 5%- 10% in 65 cases (23%), 10%- 50% in 47 
cases (17%) and 24 cases (9%) showed more than 50% immunoex-
pression (Figure 1B).
According to our miRNA array, data showed that miR- 193a- 3p 
was significantly upregulated in CD44(+) cells (3.0942- fold, P < .05) 
compared with CD44(−) cells.17 In order to validate our miRNA array 
data, we carried out real- time PCR on independent sets of CD44(+) 
and CD44(−) cells. Expression pattern of miR- 193a- 3p in CD44(+) 
and CD44(−) cells was consistent with the miRNA array data. In 
MKN45 CD44(+) cells, level of miR- 193a- 3p was approximately 
fivefold higher than in CD44(−) cells. In the other two gastric cancer 
cell lines, KATO III and AGS, similar patterns of miR- 193a- 3p expres-
sion were observed (Figure 1C). Similarly, luciferase activity of miR- 
193a- 3p was increased in CD44(+) compared to CD44(−) MKN45 
cells (Figure 1D).
3.2 | SRSF2, a miR- 193a- 3p target gene, is 
downregulated in CD44(+) MKN45 cells
Next, we investigated the candidate targets of miR- 193a- 3p such 
as SRSF2, E2F1, E2F6, MCL1 and PCNA (TargetScan and miRNA.
org website).18 We conducted real- time PCR to evaluate the ex-
pression levels of these candidates and found that SRSF2 and 
E2F1 showed differential expression in CD44(+) and CD44(−) 
cells (Figure 2A). SRSF2 (also known as SC35) is a member of the 
serine/arginine- rich protein (SR protein) family and plays a role 
in pre- mRNA splicing. SR proteins are known to form a complex, 
termed the spliceosome; this complex also includes snRNPs. The 
spliceosome is known to carry out important functions, such as al-
ternative splicing and post- splicing.19 Western blotting and immu-
nofluorescence assays confirmed decreased expression of SRSF2 
in CD44(+) compared with CD44(−) cells (Figure 2B,C). Moreover, 
the luciferase activity of SRSF2 was lower in CD44(+) than in 
CD44(−) cells (Figure 2D).
3.3 | SRSF2 regulates apoptosis- related genes
SRSF2 is known to regulate the alternative splicing of Bcl- X and 
caspase 9 in favor of pro- apoptotic splice variants.20 In order to 
confirm this function of SRSF2 in our system, we evaluated mRNA 
and protein expression level of Bcl- XL (an anti- apoptotic variant of 
Bcl- X) and caspase 9a (a pro- apoptotic variant of caspase 9). Bcl- XL 
was upregulated in CD44(+) cells, whereas caspase 9a was down-
regulated in CD44(+) cells. We also examined the expression of 
mitochondrial apoptosis- related genes on both mRNA and protein 
levels. Bax and cytochrome C such as pro- apoptotic genes were 
downregulated, whereas an anti- apoptotic gene, such as Bcl- 2, was 
upregulated in CD44(+) cells. Caspase 3 and caspase 9 are known 
to undergo cleavage during apoptosis, thereby generating increase 
in the cleaved forms of these proteins. We found that levels of 
cleaved caspase 3 and caspase 9 were both decreased in CD44(+) 
cells (Figure 3).
3.4 | CD44(+) cells induce cisplatin resistance 
compared with CD44(−) cells
We conducted MTS assays to examine the proliferative capaci-
ties of CD44(+) and CD44(−) cells upon cisplatin treatment. After 
72 hours of cisplatin treatment, different viabilities were observed 
for CD44(+) and CD44(−) cells. CD44(+) cells were more resistant 
to cisplatin than CD44(−) cells (Figure 4A). To examine the rate of 
induction of apoptosis, CD44(+) and CD44(−) cells were treated with 
or without 3 μg/mL cisplatin. After 24 hours, cells were stained with 
annexin V and propidium iodide (PI) and analyzed by flow cytometry. 
CD44(−) cells were more apoptotic than CD44(+) cells. Moreover, 
cisplatin treatment induced significantly more apoptosis in CD44(−) 
cells, whereas CD44(+) cells were largely unaffected by cisplatin 
(Figure 4B).
3.5 | Inhibition of miR- 193a- 3p increases SRSF2 
expression in CD44(+) cells
To study changes in CD44(+) cells resulting from the expression of 
miR- 193a- 3p, we transfected miR- 193a- 3p inhibitor into CD44(+) 
cells. At 48 hours post- transfection, we carried out real- time PCR 
to determine the expression level of miR- 193a- 3p in CD44(+) cells 
transfected with a negative control or the miR- 193a- 3p inhibitor. 
We found that miR- 193a- 3p expression was effectively down-
regulated by its inhibitor (Figure 5A). Moreover, we observed that 
SRSF2 of the miR- 193a- 3p target increased mRNA expression after 
downregulation of miR- 193a- 3p (Figure 5B). Protein level of SRSF2 
was also examined by western blot analysis of cell lysates and by 
immunofluorescence assays. By both of these techniques, the level 
of SRSF2 increased upon inhibition of miR- 193a- 3p in CD44(+) cells 
(Figure 5C,D). Also, the luciferase activity of SRSF2 was greater in 
CD44(+) cells transfected with the miR- 193a- 3p inhibitor than in a 
negative control (Figure 5E).
3.6 | Inhibition of miR- 193a- 3p activates the 
mitochondrial apoptotic signaling pathway
We next examined mRNA expression levels of SRSF2 targets such 
as Bcl-XL, caspase 9a and other selected pro- and anti- apoptotic 
genes by real- time PCR. Bcl-XL and caspase 9a showed changes 
in expression after transfection of the miR- 193a- 3p inhibitor into 
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F IGURE  1 Expression of microRNA (miR)- 193a- 3p in CD44(+) and CD44(−) gastric cancer cells. A, CD44 expression analysis in MKN45, 
AGS and KATO III by FACS. B, Left panel; Immunohistochemistry analysis of CD44 expression in representative tumor tissues (a, CD44- 
negative expression, the staining area in less than 5% of entire tumor. b, CD44-one positive expression means that CD44 1+, weak staining 
in 5-10% of cells. c, CD44-two positive expression means that  CD44 2+, moderate staining in 10%-50% of cells. d, CD44-three positive 
expression means that CD44 3+, strong staining in more than 50% of cells. Original magnification ×200). Right panel; Distribution of CD44 
immunoexpression in tumor tissue from 277 patients. Tumor samples were classified into four groups (<5% [n = 141], 5%- 10% [n = 65], 
10%- 50% [n = 47] and >50% [n = 24]) based on the percentage of CD44 immunostaining. C, Real- time PCR analysis of the expression of 
miR- 193a- 3p in three cell lines: MKN45, KATO III and AGS. Cells were sorted according to the presence of CD44 by FACS. Level of miR- 
193a- 3p was normalized by β- actin and is presented as the relative ratio. D, Luciferase activity assay to examine the activity of miR- 193a- 3p 
in CD44(+) and CD44(−) MKN45 cells. Data are expressed as a ratio of Firefly to Renilla luciferase activity. Each treatment was carried out in 
triplicate (*P < .05)
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CD44(+) cells. Pro- apoptotic genes such as Bax and cytochrome 
C were upregulated on the transcriptional level, whereas anti- 
apoptotic genes such as Bcl-2 was downregulated on the tran-
scriptional level in CD44(+) cells transfected with the miR- 193a- 3p 
inhibitor (Figure 6A). We carried out western blot analysis to 
measure protein levels of these gene products along with cleaved 
caspase 3 and caspase 9. The results corroborated the real- time 
PCR results. Bcl- XL and Bcl- 2 were downregulated, whereas Bax, 
cytochrome C, cleaved caspase 3 and cleaved caspase 9 were all 
upregulated in miR- 193a- 3p- inhibited CD44(+) cells (Figure 6B). 
Immunofluorescence assays confirmed the expression and lo-
calization of Bcl- XL in negative control- transfected CD44(+) and 
CD44(−) cells or miR- 193a- 3p inhibitor- transfected CD44(+) cells 
(Figure 6C).
3.7 | Inhibition of miR- 193a- 3p sensitizes CD44(+) 
cells to cisplatin
We determined the viabilities of negative control- transfected 
CD44(+) and CD44(−) cells or miR- 193a- 3p inhibitor- transfected 
CD44(+) cells after cisplatin treatment. CD44(+) cells were more 
viable than miR- 193a- 3p- inhibited CD44(+) cells and CD44(−) cells 
under cisplatin treatment. The viabilities of miR- 193a- 3p- inhibited 
CD44(+) cells and CD44(−) cells were not statistically significantly 
different (Figure 7A). We also detected apoptotic cells by annexin 
V staining, followed by flow cytometry analysis. These experiments 
indicated that CD44(+) cells were more resistant to cisplatin than 
miR- 193a- 3p- inhibited CD44(+) cells or CD44(−) cells (Figure 7B). To 
observe the nuclear morphologies in each cell type, we stained cells 
F IGURE  2 Expression of microRNA 
(miR)- 193a- 3p target gene, SRSF2 in 
CD44(+) and CD44(−) gastric cancer cells. 
A, Real- time PCR analysis of the mRNA 
expression levels of several candidate 
miR- 193a- 3p target genes, including 
SRSF2, E2F1, E2F6, MCL1 and PCNA in 
CD44(+) and CD44(−) MKN45 cells. Level 
of miR- 193a- 3p target genes normalized 
by β- actin and presented as the relative 
ratio. B, Western blot analysis of SRSF2 
expression in CD44(+) and CD44(−) 
MKN45 cells. C, Immunofluorescence 
assays to detect the expression of SRSF2 
(green) in CD44(+) and CD44(−) MKN45 
cells. Nuclei (blue) were counterstained 
with DAPI. D, Luciferase activity assay to 
examine the activity of SRSF2 in CD44(+) 
and CD44(−) MKN45 cells. Data are 
expressed as a ratio of Firefly to Renilla 
luciferase activity. Each treatment was 
carried out in triplicate (*P < .05)
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with DAPI. Both miR- 193a- 3p- inhibited CD44(+) cells and CD44(−) 
cells formed more apoptotic bodies and showed more irregular nuclei 
after cisplatin treatment compared with CD44(+) cells (Figure 7C).
4  | DISCUSSION
Although gastric cancer incidence is now declining, gastric cancer 
mortality is still significantly high. Surgical and systemic treatment 
as well as screening, early detection, and treatment strategies for 
Helicobacter pylori infection for gastric cancer are still major health 
burdens worldwide.21 Cisplatin is commonly used for adjuvant chem-
otherapy in advanced- stage gastric cancer patients. Cisplatin has 
been characterized as a DNA linkage agent, and the cytotoxicity of 
cisplatin has generally contributed to the ability to form intra- strand 
and inter- strand DNA linkage.22 Cisplatin may cause mitochondrial 
alterations leading to activation of apoptosis or cell death and also 
oxidative/reticular stress. In many different aspects, cisplatin resist-
ance has been proposed (pre- , on- , post- , and off- target). In the pre- 
target aspect, several transporters were identified as associated with 
cisplatin resistance, such as copper transporter 1 (CTR1), copper- 
transporting ATPase (ATP7B), multidrug resistance- associated 
protein 2 (MRP2), and volume- regulated anion channels (VRAC). 
On- target resistance includes excision repair cross- complementing 
rodent repair deficiency and complementation group 1 (ERCC1). 
Also, bcl- 2 family members and the akt pathway are implicated in 
the post- and off- target mechanisms in cisplatin resistance.5
CD44 is well known as a proven gastric cancer stem cell marker 
and known to play a critical role in regulating self- renewal, tumor 
F IGURE  3 Expression of pro- and anti- apoptotic genes 
downstream of SRSF2 in CD44(+) and CD44(−) cells. A, Real- time 
PCR analysis of mRNA expression for splice variants of genes 
downstream of SRSF2 in CD44(+) and CD44(−) MKN45 cells. 
Downstream pro- apoptotic genes: Bcl-XL and Bcl-2. Downstream 
anti- apoptotic genes: Bax, cytochrome C and caspase 9a. Expression 
of SRSF2- related pro- and anti- apoptotic genes was normalized 
by β- actin and is presented as the relative ratio. B, Western blot 
analysis of Bcl- XL, Bcl- 2, Bax, cytochrome C, cleaved caspase 3 and 
cleaved caspase 9 in CD44(+) and CD44(−) MKN45 cells. Cyt C, 
cytochrome C; cleaved Casp 3, cleaved caspase 3; cleaved Casp 9, 
cleaved caspase 9
F IGURE  4 Cisplatin resistance in CD44(+) and CD44(−) cells. A, 
Viabilities of CD44(+) and CD44(−) MKN45 cells after treatment 
with cisplatin (2 or 2.5 μg/mL) as measured by MTS assay. Values 
shown represent averages of relative control cell viabilities; each 
treatment was carried out in triplicate (*P < .05). B, CD44(+) and 
CD44(−) MKN45 cells were treated with cisplatin (3 μg/mL) for 
24 h and then stained with annexin V and propidium iodide. 
Values shown represent average rates of apoptosis after cisplatin 
treatment of CD44(+) and CD44(−) MKN45 cells. Each treatment 
was carried out in triplicate (*P < .05). CDDP, cisplatin
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initiation, metastasis and chemoresistance. Also, CD44 positivity is 
associated with poor prognosis in various human cancers, including 
breast, brain, colon, pancreatic, and gastric cancers.16 Previously, 
we carried out miRNA microarray analysis and found multiple miR-
NAs that were differentially expressed in CD44(+) and CD44(−) 
MKN45 cells.17 miRNA regulation has previously been examined to 
be a characteristic of cancer stem cells. Among these differentially 
expressed miRNAs, we focused on miR- 193a- 3p which was signifi-
cantly upregulated in CD44(+) cells compared with CD44(−) cells. 
Although the role of miR- 193a- 3p has remained largely uncharac-
terized, several studies have recently focused on this miRNA in vari-
ous cancers. In renal cancer tissue, miR- 193a- 3p was shown to have 
increased expression compared with normal tissue.23 Interestingly, 
miR- 193a- 3p regulates the expression of c- kit through a mecha-
nism involving promoter methylation in acute myeloid leukemia.24 
However, the mechanism of miR- 193a- 3p- dependent cisplatin re-
sistance response underlying gastric cancer stemness has not been 
fully elucidated.
In the present study, we first investigated known targets of miR- 
193a- 3p and the signaling pathways regulated by these targets. Using 
real- time PCR analysis, we found that the expression level of miR- 
193a- 3p was inversely correlated with levels of SRSF2 and E2F1. We 
chose SRSF2 as a target of miR- 193a- 3p because its expression level 
showed a large difference between CD44(+) and CD44(−) cells. It has 
F IGURE  5 Expression of microRNA (miR)- 193a- 3p and its target gene, SRSF2 in CD44(+) and miR- 193a- 3p- inhibited CD44(+) cells. A, 
Real- time PCR analysis of the expression of miR- 193a- 3p in negative control or miR- 193a- 3p inhibitor- transfected CD44(+) MKN45 cells. 
Level of miR- 193a- was normalized by β- actin and is presented as the relative ratio. B, Real- time PCR analysis of miR- 193a- 3p target gene 
SRSF2 in negative control or miR- 193a- 3p inhibitor- transfected CD44(+) MKN45 cells. Expression of the SRSF2 gene normalized by β- actin 
and presented as the relative ratio. C, Western blot analysis of SRSF2 in negative control or miR- 193a- 3p inhibitor- transfected CD44(+) 
MKN45 cells. D, Immunofluorescence assay to examine the expression of SRSF2 (green) in negative control or miR- 193a- 3p inhibitor- 
transfected CD44(+) MKN45 cells. Nuclei were counterstained with DAPI (blue). miR- 193a INH, miR- 193a- 3p inhibitor; NC, negative control. 
E, Luciferase activity assay to examine the activity of SRSF2 in negative control or miR- 193a- 3p inhibitor- transfected CD44(+) MKN45 cells. 
Data are expressed as a ratio of Firefly luciferase activity to Renilla luciferase activity
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already been reported that a certain transcription factor, E2F1, targets 
and causes increased expression of SRSF2.25 SRSF2 is known to play a 
role in determining active splice sites during the pre- mRNA alternative 
splicing process. Moreover, SRSF2 has been implicated in apoptosis, 
as promoted by cisplatin in lung cancer.26 Most human genes undergo 
alternative splicing in order to make a large number of proteins capa-
ble of carrying out a variety of roles. In apoptosis, mRNA pre- splicing 
is a crucial factor controlling downstream pathways. Many proteins 
involved in apoptosis pathways are expressed as multiple isoforms, 
each of which plays a distinctive role.27 Bcl- X, one of the most studied 
genes to undergo alternative splicing is known to occur in two iso-
forms: Bcl- XL and Bcl- XS. Bcl- XL shows anti- apoptotic effects, whereas 
Bcl- XS provokes apoptosis. Caspase 9 was spliced into caspase 9a, an 
isoform known to exert pro- apoptotic effects.28
Next, we evaluated the expression levels of selected genes 
downstream of SRSF2 in addition to levels of mitochondrial 
apoptotic molecules. Bcl- XL, an anti- apoptotic variant of Bcl- X was 
increased, whereas caspase 9a, a pro- apoptotic variant of caspase 
9 was decreased by the downregulated SRSF2 in CD44(+) cells. The 
pro- apoptotic genes Bax, cytochrome C, cleaved caspase 3 and 
cleaved caspase 9 were downregulated, whereas the anti- apoptotic 
gene Bcl- 2 was upregulated in CD44(+) cells compared with CD44(−) 
cells. After cisplatin treatment, CD44(+) cells with inactivated 
apoptotic genes showed higher survival rates than CD44(–) cells. 
We suppressed miR- 193a- 3p expression in CD44(+) cells using a 
miR- 193a- 3p inhibitor and investigated the resulting effects on the 
regulation of mitochondrial apoptotic pathways. Contrastively, the 
level of SRSF2 increased and its target genes were suppressed in 
miR- 193a- 3p- inhibited CD44(+) cells. Inhibition of miR- 193a- 3p also 
resulted in increased sensitivity to cisplatin treatment and showed 
a similar rate of apoptosis to that in CD44(−) cells. Despite the fact 
that miR- 193a- 3p expression correlated with cisplatin resistance 
F IGURE  6 Expression of pro- and anti- apoptotic genes downstream of SRSF2 in CD44(+) and microRNA (miR)- 193a- 3p- inhibited 
CD44(+) cells. A, Real- time PCR analysis of Bcl-XL, caspase 9a, Bax, cytochrome C and Bcl-2 in negative control or miR- 193a- 3p inhibitor- 
transfected CD44(+) MKN45 cells. Expression of the pro- and anti- apoptotic genes related to SRSF2 was normalized by β- actin and is 
presented as the relative ratio. B, Western blot analysis of Bcl- XL, Bcl- 2, Bax, cytochrome C, cleaved caspase 3 and cleaved caspase 9 in 
negative control or miR- 193a- 3p inhibitor- transfected CD44(+) MKN45 cells. C, Immunofluorescence assay to examine the expression of 
Bcl- XL (green) in negative control or miR- 193a- 3p inhibitor- transfected CD44(+) MKN45 cells. Mitochondria were stained with MitoSOX (red) 
and nuclei were counterstained with DAPI (blue). Cyt C, cytochrome C; cleaved Casp 3, cleaved caspase 3; cleaved Casp 9, cleaved caspase 
9; miR- 193a INH, miR- 193a- 3p inhibitor; NC, negative control
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in CD44(+) cells, it is still considered largely experimental data. 
Therefore, further studies adopting the regulation of miR- 193a- 3p 
expression in the animal model of gastric cancer may warrant the 
possibility of clinical application in the future.
These results suggest that the upregulation of miR- 193a- 3p can 
inhibit cisplatin- induced mitochondrial apoptosis in CD44(+) gastric 
cancer cells. Thus, regulating miR- 193a- 3p might be an attractive 
treatment strategy to target cisplatin- resistant cells in gastric cancer.
F IGURE  7 Cisplatin resistance 
in CD44(+), CD44(–) and microRNA 
(miR)- 193a- 3p- inhibited CD44(+) cells. 
A, MTS assays of cell viability after 
cisplatin treatment (2 or 2.5 μg/mL) of 
negative control- transfected CD44(+), 
negative control- transfected CD44(−) 
and miR- 193a- 3p inhibitor- transfected 
CD44(+) MKN45 cells. Values shown 
represent averages of relative control cell 
viabilities; each experiment was carried 
out in triplicate (*P < .05). B, Apoptosis 
measurements in negative control- 
transfected CD44(+), negative control- 
transfected CD44(−) and miR- 193a- 3p 
inhibitor- transfected CD44(+) MKN45 
cells after cisplatin treatment (3 μg/mL). 
Cells were stained with annexin V and 
propidium iodide and analyzed by flow 
cytometry. Values represent average 
rates of apoptosis in each cell type, 
from triplicate experiments (*P < .05). C, 
Fluorescence images of representative 
nuclei from negative control- transfected 
CD44(+), negative control- transfected 
CD44(−) and miR- 193a- 3p inhibitor- 
transfected CD44(+) MKN45 cells. Nuclei 
were stained with DAPI to observe their 
morphologies. White arrows indicate 
apoptotic bodies. CDDP, cisplatin; CON, 
control; miR- 193a INH, miR- 193a- 3p 
inhibitor; NC, negative control; ns, not 
significant
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